A/Prof Duncan Campbell

Research Unit

Molecular cardiology


Principal Research Associate
Associate Professor and Principal Fellow (Honorary), University of Melbourne, Department of Medicine, St. Vincent's Hospital
Physician (Honorary), St. Vincent's Hospital, Victoria, Australia

Professional Experience

1973     BMedSc University of Melbourne, Victoria, Australia
1973     MBBS University of Melbourne, Victoria, Australia
1980     Fellow Royal Australasian College of Physicians
1982     PhD
1997     GradDipEpidBiostat, University of Melbourne, Victoria, Australia
2005     Fellow Cardiac Society of Australia and New Zealand


1982       Royal Australasian College of Physicians Bushell Travelling Fellowship
1982       Postdoctoral Research Fellowship from INSERM, France
1983-85  NHMRC C.J. Martin Fellowship
1986-87  NHMRC C.J. Martin Fellowship
1985-86  International Research Fellowship
               Fogarty International Centre, NIH, USA
1986       Demuth Young Investigator Award, International Society of Hypertension

Research Interests

Cardiovascular disease, hypertension, cardiac failure, renin-angiotensin system, kallikrein kinin system, natriuretic peptides.

Selected Publications

  1. Campbell DJ. Clinical relevance of local renin angiotensin systems. Frontiers in Endocrinology (Lausanne) 2014;5:113.
  2. Zhu T, Miller AG, Deliyanti D, Berka DR, Agrotis A, Campbell DJ, Wilkinson-Berka JL. Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. Clinical and Experimental Pharmacology and Physiology 2015;42:537-548.
  3. Prior DL, Somaratne JB, Jenkins AJ, Yii M, Newcomb AE, Schalkwijk CG, Black MJ, Kelly DJ, Campbell DJ. Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. Open Heart 2015;2:e000278
  4. Boffa U, McGrady M, Reid CM, Shiel L, Wolfe R, Liew D, Campbell DJ, Stewart S, Krum H. SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF): early detection of chronic heart failure in the workplace. Australian Health Review Aust Health Rev. 2017 41:121-126.
  5. Campbell DJ. The Clinical Utility Curve: a proposal to improve the translation of information provided by prediction models to clinicians. BMC Research Notes 2016;9:219.
  6. Campbell DJ. Therapeutic modulation of tissue kallikrein expression. Biological Chemistry 2016;397:1293-1297.
  7. Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs. Nature Reviews Cardiology 2017;14:171-186.
  8. Campbell DJ. Clinical utility curve assists clinical decision making. Atlas of Science. 2016.
  9. Campbell DJ. Can cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved? BMC Cardiovascular Disorders 2016;16:221.
  10. Roberts V, Campbell DJ, Lu B, Chia J, Cowan PJ, Dwyer KM. The differential effect of apyrase treatment and hCD39 overexpression on chronic renal fibrosis following ischemia reperfusion injury. Transplantation 2017;101:e194-e204.
  11. Gong FF, Campbell DJ, Prior DL. Non-invasive cardiac imaging and the prediction of heart failure progression in pre-clinical stage A/B subjects. JACC: Cardiovascular Imaging 2017;10:1504-1519.
  12. Campbell DJ, Coller JM, Gong FF, McGrady M, Prior DL, Boffa U, Shiel L, Liew D, Wolfe R, Owen AJ, Krum H, Reid CM. Risk factor management in a contemporary Australian population at increased cardiovascular risk. Internal Medicine Journal 2018;48:688–698.
  13.  Gong FF, Jelinek MV, Castro JM, Coller JM, McGrady M, Boffa U, Shiel L, Liew D, Wolfe R, Stewart S, Owen AJ, Krum H, Reid CM, Prior DL, Campbell DJ. Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. Open Heart 2018;5:e000782.2.
  14. Campbell DJ. Neprilysin inhibitors and bradykinin. Frontiers in Medicine 2018;5:257.
  15. Campbell DJ, Gong FF, Jelinek MV, Castro JM, Coller JM, McGrady M, Boffa U, Shiel L, Wang BH, Liew D, Wolfe R, Stewart S, Owen AJ, Krum H, Reid CM, Prior DL. Prediction of incident heart failure by serum NT-proBNP level in a community-based cohort. European Journal of Heart Failure 2019;(available online).